BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20149324)

  • 1. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.
    Rios Fernández R; Callejas Rubio JL; Sánchez Cano D; Sáez Moreno JA; Ortego Centeno N
    Clin Exp Rheumatol; 2009; 27(6):1009-16. PubMed ID: 20149324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
    Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
    Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
    Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
    Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
    García Hernández FJ; Chinchilla Palomares E; Castillo Palma MJ; González Pulido C; Ocaña Medina C; Sánchez Román J
    Med Clin (Barc); 2010 Jul; 135(6):256-9. PubMed ID: 20537666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of polymyositis and dermatomyositis.
    Marie I; Mouthon L
    Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
    Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
    Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of cardiac involvement in dermatomyositis with rituximab.
    Touma Z; Arayssi T; Kibbi L; Masri AF
    Joint Bone Spine; 2008 May; 75(3):334-7. PubMed ID: 17988919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients.
    Majmudar S; Hall HA; Zimmermann B
    J Clin Rheumatol; 2009 Oct; 15(7):338-40. PubMed ID: 20009968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
    Levine TD
    Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
    Lazarou IN; Guerne PA
    J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in the treatment of refractory dermatomyositis.
    Chiappetta N; Steier J; Gruber B
    J Clin Rheumatol; 2005 Oct; 11(5):264-6. PubMed ID: 16357773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.